Benign prostatic hyperplasia (BPH) is the most common tumor in aging men, and is associated with lower urinary tract symptoms (LUTS). Treatment options include watchful waiting, life-style modification, pharmacologic treatment, and surgery. Alpha-adrenergic receptor blockers (α-blockers) decrease LUTS and increase urinary flow rates in men with symptomatic BPH. 5- Alpha-reductase inhibitors (5-ARIs) decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume. For patients with moderate to severe symptoms and a large prostate, combination therapy with α-blockers and 5-ARIs can further improve clinical efficacy of treatment. Numerous plant-based products (phytomedicines) are increasingly used as an alternative or complement the conventional medication. For some patients, phosphodiesterase-5 inhibitors (PDE5-Is) or antimuscarinic agents may be added. Here, we discuss the current pharmacotherapy of BPH.
Benign prostatic hyperplasia; lower urinary tract symptoms; pharmacotherapy; Western medicine; Chinese herbal medicine, Review